Correction: Axl is a logical molecular target research in head and neck squamous cell carcinoma (Clin Cancer Res) (2018) 21 (2601–2612) DOI :10.1158/1078-0432.CCR-14-2648);AXLIs a logical molecular target in headand neck squamous cell carcinoma

Clinical Cancer Research

Volumn 21, Issue 11, 2015, Pages 2601-2612

  Brand, Toni M ^a   Iida, Mari ^a   Stein, Andrew P ^a   Corrigan, Kelsey L ^a   Braverman, Cara M ^a   Coan, John P ^a   Pearson, Hannah E ^a   Bahrar, Harsh ^a   Fowler, Tyler L ^a   Bednarz, Bryan P ^a   Saha, Sandeep ^a   Yang, David ^a   Gill, Parkash S ^b   Lingen, Mark W ^c   Saloura, Vassiliki ^d   Villaflor, Victoria M ^d   Salgia, Ravi ^d   Kimple, Randall J ^a   Wheeler, Deric L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; R 428; RECEPTOR TYROSINE KINASE AXL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; FUSED ALICYCLIC AROMATIC COMPOUND; ONCOPROTEIN; R428 COMPOUND; TRIAZOLE DERIVATIVE;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIVITY; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME INHIBITION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH CARE QUALITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; PATHOGENESIS; PRIORITY JOURNAL; RADIOSENSITIVITY; RECURRENCE FREE SURVIVAL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK NEOPLASMS; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BENZOCYCLOHEPTENES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941965392     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-18-3194     Document Type: Erratum

References (55)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
3. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010;21 (Suppl 7):vii252-61.
4. Posner MR, Haddad RI, Wirth L, Norris CM, Goguen LA, Mahadevan A, et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 2004;31:778-85.
5. Vermorken JB. Medical treatment in head and neck cancer. Ann Oncol 2005;16 Suppl 2:ii258-64.
6. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
7. Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, et al. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: eastern cooperative oncology group trial E3303. Clin Cancer Res 2014;20: 5041-51.
8. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
9. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012;44:852-60.
10. Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human nonsmall cell lung cancer. Oncogene 2013;32:3420-31.
11. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013;19: 279-90.
12. Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 2009;28:3442-55.
13. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, et al. An anti- Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 2010;29: 5254-64.
14. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, et al. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 2005;7:1058-64.
15. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010;70:1544-54.
16. Meyer AS, Miller MA, Gertler FB, Lauffenburger DA. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal 2013;6:ra66.
17. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008;68:1905-15.
18. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 2014;33: 1316-24.
19. D'Alfonso TM, Hannah J, Chen Z, Liu Y, Zhou P, Shin SJ. Axl receptor tyrosine kinase expression in breast cancer. J Clin Pathol 2014;67: 690-6.
20. Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, et al. AXL is an essential factor and therapeutic target formetastatic ovarian cancer. Cancer Res 2010;70:7570-9.
21. Dunne PD, McArt DG, Blayney JK, Kalimutho M, Greer S, Wang T, et al. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin Cancer Res 2014;20:164-75.
22. Giles KM, Kalinowski FC, Candy PA, Epis MR, Zhang PM, Redfern AD, et al. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther 2013;12:2541-58.
23. Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, Krishnamoorthy G, et al. Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res 2011;71:1792-804.
24. Paccez JD, Vasques GJ, Correa RG, Vasconcellos JF, Duncan K, Gu X, et al. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene 2013;32:689-98.
25. Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, Abbruzzese JL, et al. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 2011;117: 734-43.
26. Han J, Tian R, Yong B, Luo C, Tan P, Shen J, et al. Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients. Biochem Biophys Res Commun 2013;435: 493-500.
27. Liu R, Gong M, Li X, Zhou Y,Gao W, Tulpule A, et al. Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood 2010;116:297-305.
28. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008;100:35-83.
29. Feneyrolles C, SpenlinhauerA, Guiet L, Fauvel B, Dayde-Cazals B, Warnault P, et al. Axl kinase as a key target for oncology: focus on small molecule inhibitors. Mol Cancer Ther 2014;13:2141-8.
30. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, et al. AXL mediates resistance to cetuximab therapy. Cancer Res 2014;74: 5152-64.
31. Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon SJ, et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res 2014;74:253-62.
32. Li C, Brand TM, Iida M, Huang S, Armstrong EA, van der Kogel A, et al. Human epidermal growth factor receptor 3 (HER3) blockade with U3- 1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discov Med 2013;16:79-92.
33. Fowler TL, Fulkerson RK, Micka JA, Kimple RJ, Bednarz BP. A novel highthroughput irradiator for in vitro radiation sensitivity bioassays. Phys Med Biol 2014;59:1459-70.
34. Fowler TL, Bailey AM, Bednarz BP, Kimple RJ. High-throughput detection of DNA double-strand breaks using image cytometry. BioTechniques 2014;58:37-9.
35. Kimple RJ, Smith MA, Blitzer GC, Torres AD, Martin JA, Yang RZ, et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res 2013;73:4791-800.
36. Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M, et al. Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res 2013;19:855-64.
37. Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010;28:4142-8.
38. Wnuk-Lipinska K, Tiron C, Gausdal G, Sandal T, Frink R, Hinz S, et al. BGB324, a selective small molecule Axl kinase inhibitor to overcome EMTassociated drug resistance in carcinomas: therapeutic rationale and early clinical studies [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract nr 1747.
39. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
40. Chou TC. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res 2010;70:440-6.
41. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
42. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, et al. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 2009;8:696-703.
43. Iida M, Brand TM, Campbell DA, Li C, Wheeler DL. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene 2013;32:759-67.
44. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009;28:3801-13.
45. Schmidt-Ullrich RK, Contessa JN, Lammering G, Amorino G, Lin PS. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 2003;22:5855-65.
46. Meyn RE, Munshi A, Haymach JV, Milas L, Ang KK. Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol 2009;92:316-22.
47. Peng Y, Zhang Q, Nagasawa H, Okayasu R, Liber HL, Bedford JS. Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer Res 2002;62:6400-4.
48. ToulanyM, Kehlbach R, Florczak U, Sak A, Wang S, Chen J, et al. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 2008;7:1772-81.
49. Wilson C, Ye X, Pham T, Lin E, Chan S, McNamara E, et al. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Res 2014; 74:5878-90.
50. Basu D, Nguyen TTK, Montone KT, Zhang G, Wang LP, Diehl JA, et al. Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene 2010;29:4170-82.
51. Hong AM, Dobbins TA, Lee CS, Jones D, Harnett GB, Armstrong BK, et al. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 2010;103:1510-7.
52. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9.
53. Weinberger PM, Yu Z, Kountourakis P, Sasaki C, Haffty BG, Kowalski D, et al. Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of three-class hypothesis. Otolaryngol Head Neck Surg 2009;141:382-9.
54. Strati K, Pitot HC, Lambert PF. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A 2006;103:14152-7.
55. Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsague X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16(INK4a) detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 2014;15: 1319-31.